Multiple myeloma (MM), a challenging and often relentless blood cancer, has long been difficult to treat with traditional methods. Standard therapies have included chemotherapy, immunomodulatory drugs, proteasome inhibitors, and stem cell transplants. However, a groundbreaking approach is emerging on the horizon—bispecific antibodies. These novel agents are redefining the treatment...
English
Français
Español
Português
Deutsch
Türkçe
Dutch
Italiano
Russian
Romaian